Axial spondyloarthritis

Axial spondyloarthritis

Cimzia is the first anti-TNF to demonstrate sustained remission at a reduced maintenance dose.^1-8

Jump Menu

Off

Did you know?

Cimzia is indicated for the treatment of adult patients with severe active axial spondyloarthritis¹

Click here to visit emc for the full indication details (SmPC)

Off

Key studies

Study to Evaluate Maintenance of Sustained Remission of axSpA With CZP Compared to Placebo (C-OPTIMISE)

Key study

Study design

A two-part, phase 3b multicentre study evaluating maintenance of remission in adult patients with early active axSpA (radiographic or non-radiographic axSpA)

View this study

See Also

C-View

C-axSpAnd

RAPID-axSpA

CRIB

CRADLE

Off

Efficacy

See the wealth of efficacy data offered by Cimzia in axSpA: Key Efficacy Trial Data

Key study

Efficacy by section

Reduced maintenance dosing Radiographic progression Improving pain and fatigue

View this data

See Also

C-View

C-axSpAnd

RAPID-axSpA

CRIB

CRADLE

Off

Safety profile

Cimzia in axSpA: Key Safety Profile Data

Key study

Safety data

Cimzia was initially studied in 325 patients with active axial spondyloarthritis (including ankylosing spondylitis and non-radiographic axial spondyloarthritis)

View data

See Also

C-View

C-axSpAnd

RAPID-axSpA

CRIB

CRADLE

Off

Dosing

Dosing and administration across all indications¹

Key study

Dosing guide

Cimzia maintenance dosing regimen is preceded by a loading dose across all indications¹

See dosing guide

See Also

A step-by-step guide to injecting with the Cimzia AutoClicks pre-filled pen

Step-by-step guide to injecting with the Cimzia pre-filled syringe

Off

Unique molecular structure

Cimzia is a PEGylated, FC free anti-TNF¹

Key study

FC free anti-TNF

Cimzia is the first PEGylated, FC free anti-TNF indicated for the treatment of severe active Axial Spondyloarthritis, active Psoriatic Arthritis, moderate to severe Plaque Psoriasis, and moderate to severe Rheumatoid Arthritis inadequately controlled with prior therapy.^1,6,10-12

Cimzia's licensed indications include the treatment of adult patients with severe active Axial Spondyloarthritis (axSpa), active Psoriatic Arthritis (PsA), moderate to severe Plaque Psoriasis (PSO), and moderate to severe Rheumatoid Arthritis (RA) inadequately controlled with prior therapy.¹

These are not the full licensed indications of Cimzia. Please refer to the SmPC for further information.

Off

Women of childbearing age

Reducing the treatment burden for women of childbearing age

Due to the emerging biosimilar market, trusts are being encouraged to use the best value biologic as the first line option.⁹ In addition to financial costs, it is important to consider the wider impact on the patient, their family and the NHS when a patient is on a treatment journey e.g. switching treatments, repeated hospital visits, loss of work days.¹⁰

Sandra's Story
(Cimzia should only be used during pregnancy if clinically needed.¹ )

Key study

Sandra's Story

A hypothetical journey for a patient

View here

See Also

CRIB

CRADLE

Off

References

Cimzia^® Summary of Product Characteristics. [Accessed October 2022].
Landewé R, et al. Ann Rheum Dis. 2020;79(7):920–928.
Enbrel^® Summary of Product Characteristics. [Accessed October 2022].
Remicade^® Summary of Product Characteristics. [Accessed October 2022].
Humira^® Summary of Product Characteristics. [Accessed October 2022].
Cosentyx^® Summary of Product Characteristics. [Accessed October 2022].
Taltz^® Summary of Product Characteristics. [Accessed October 2022].
Simpon^i® Summary of Product Characteristics. [Accessed October 2022].
NHS England 2017 Commissioning framework for biological medicines (including biosimilar medicines) https://www.england.nhs.uk/wp-content/uploads/2017/09/biosimilar-medicines-commissioning-framework.pdf [Accessed October 2022]
NHS RightCare Musculoskeletal (MSK) Workstream https://www.england.nhs.uk/rightcare/workstreams/musculoskeletal-msk/ [Accessed October 2022]

Off